Medicare won't cover anti-obesity GLP-1 drugs as Biden admin proposed

The Centers for Medicare and Medicaid (CMS) announced Friday it will not be finalizing a rule proposed by the Biden administration that would have allowed Medicare and Medicaid beneficiaries access to anti-obesity drugs such as the highly in-demand GLP-1 medications. In November last year, the Biden administration proposed a new rule that would allow drugs...